[Federal Register Volume 66, Number 121 (Friday, June 22, 2001)]
[Notices]
[Pages 33544-33545]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 01-15666]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration


Request for Interest in Participating in the Selection of the 
Nonvoting Members of Industry Interests on Public Advisory Committees; 
Nonprescription Drugs Advisory Committee

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is filling the position 
of nonvoting industry representative on the Nonprescription Drugs 
Advisory Committee. FDA requests that any industry organization, that 
is interested in participating in the selection of an appropriate 
nonvoting member of the Nonprescription Drugs Advisory Committee to 
represent industry, send a letter stating that interest to the FDA 
employee designated below within 30 days of the date of this notice. In 
addition, if individuals or organizations would like to nominate 
individuals to serve as the nonvoting industry representative, they may 
do so.

DATES: Letters of interest and nominations should be received on or 
before July 23, 2001.

ADDRESSES: All nominations for membership should be submitted to Sandra 
Titus (address below).

FOR FURTHER INFORMATION CONTACT: Sandra Titus, Advisors and Consultants 
Staff (HFD-21), Center for Drug Evaluation and Research, Food and Drug 
Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-7001, 
e-mail: <a href="/cdn-cgi/l/email-protection#1b6f726f6e68685b787f7e69357d7f7a357c746d"><span class="__cf_email__" data-cfemail="d2a6bba6a7a1a192b1b6b7a0fcb4b6b3fcb5bda4">[email protected]</span></a>.

SUPPLEMENTARY INFORMATION:

I. Function

    The function of the committee is to review and evaluate available 
data concerning the safety and effectiveness of over-the-counter 
(nonprescription) human drug products for use in thetreatment of a 
broad spectrum of human symptoms and diseases.

II. Selection Procedure

    Any industry organization interested in participating in the 
selection of an appropriate nonvoting member of the

[[Page 33545]]

Nonprescription Drugs Advisory Committee to represent industry 
interests should send a letter stating that interest to the FDA 
employee designated in the notice within 30 days of the date of this 
notice. After 30 days, a letter will be sent to each organization that 
has expressed an interest, attaching a complete list of all such 
organizations, and stating that it is their responsibility to consult 
with each other in selecting a single nonvoting member to represent 
industry interests for that committee within 60 days after receipt of 
the letter. If no individual is selected within 60 days, the agency 
will select the nonvoting member representing industry interests.
    Individuals and organizations may nominate individuals to serve as 
the nonvoting industry representative. To do so, a current curriculum 
vitae should be sent to the contact person. FDA will forward any 
nominations to the organizations expressing interest in participating 
in the selection process. The organizations are under no obligation to 
select any of these nominees but may do so if they wish.
    This notice is issued under the Federal Advisory Committee Act (5 
U.S.C. app. 2) and 21 CFR part 14, relating to advisory committees.

    Dated: June 14, 2001.
Linda A. Suydam,
Senior Associate Commissioner.
[FR Doc. 01-15666 Filed 6-21-01; 8:45 am]
BILLING CODE 4160-01-S


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>